The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Use of Allopurinol in Slowing the Progression of Renal Disease Through Its Ability to Lower Serum Uric Acid Level
Abstract
BACKGROUND Hyperuricemia is associated strongly with the development of hypertension, renal disease, and progression. Allopurinol decreases serum uric acid levels by inhibiting the enzyme xanthine oxidase. We hypothesized that administrating allopurinol to decrease serum uric acid levels to the normal range in hyperuricemic patients with chronic kidney disease may be of benefit in decreasing blood pressure and slowing the rate of renal disease progression in these patients. METHODS We conducted a prospective, randomized, controlled trial of 54 hyperuricemic patients with chronic kidney disease. Patients were randomly assigned to treatment with allopurinol, 100 to 300 mg/d, or to continue the usual therapy for 12 months. Clinical, hematologic, and biochemical parameters were measured at baseline and 3, 6, and 12 months of treatment. We define our study end points as: (1) stable kidney function with less than 40% increase in serum creatinine level, (2) impaired renal function with creatinine level increase greater than 40% of baseline value, (3) initiation of dialysis therapy, and (4) death. RESULTS One patient in the treatment group dropped out because of skin allergy to allopurinol. Serum uric acid levels were significantly decreased in subjects treated with allopurinol, from 9.75 +/- 1.18 mg/dL (0.58 +/- 0.07 mmol/L) to 5.88 +/- 1.01 mg/dL (0.35 +/- 0.06 mmol/L; P < 0.001). There were no significant differences in systolic or diastolic blood pressure at the end of the study comparing the 2 groups. There was a trend toward a lower serum creatinine level in the treatment group compared with controls after 12 months of therapy, although it did not reach statistical significance (P = 0.08). Overall, 4 of 25 patients (16%) in the allopurinol group reached the combined end points of significant deterioration in renal function and dialysis dependence compared with 12 of 26 patients (46.1%) in the control group (P = 0.015). CONCLUSION Allopurinol therapy significantly decreases serum uric acid levels in hyperuricemic patients with mild to moderate chronic kidney disease. Its use is safe and helps preserve kidney function during 12 months of therapy compared with controls. Results of this study need to be confirmed with an additional prospective trial involving a larger cohort of patients to determine the long-term efficacy of allopurinol therapy and in specific chronic kidney disease subpopulations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gu, L., Okada, Y., Clinton, S. K., Gerard, C., Sukhova, G. K., Libby, P., & Rollins, B. J. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80139-2 · Cited by 1,575
Serum Uric Acid and Cardiovascular Mortality: The NHANES I Epidemiologic Follow-up Study, 1971-1992
Fang, J., & Alderman, M. H. (2000) · JAMA · doi:10.1001/jama.283.18.2404 · Cited by 1,513
Is There a Pathogenetic Role for Uric Acid in Hypertension and Cardiovascular and Renal Disease?
Johnson, R. J., Kang, D.-H., Feig, D., Kivlighn, S., Kanellis, J., Watanabe, S., Tuttle, K. R., Rodriguez-Iturbe, B., Herrera-Acosta, J., & Mazzali, M. (2003) · Hypertension · doi:10.1161/01.hyp.0000069700.62727.c5 · Cited by 1,361
A Role for Uric Acid in the Progression of Renal Disease
Kang, D.-H., Nakagawa, T., Feng, L., Watanabe, S., Han, L., Mazzali, M., Truong, L., Harris, R., & Johnson, R. J. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000034910.58454.fd · Cited by 1,304
Elevated Uric Acid Increases Blood Pressure in the Rat by a Novel Crystal-Independent Mechanism
Mazzali, M., Hughes, J., Kim, Y.-G., Jefferson, J. A., Kang, D.-H., Gordon, K. L., Lan, H. Y., Kivlighn, S., & Johnson, R. J. (2001) · Hypertension · doi:10.1161/hy1101.092839 · Cited by 1,300
Kanellis, J., Watanabe, S., Li, J. H., Kang, D. H., Li, P., Nakagawa, T., Wamsley, A., Sheikh-Hamad, D., Lan, H. Y., Feng, L., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000072820.07472.3b · Cited by 786
Sanchez-Lozada, L. G., Tapia, E., Santamaria, J., Avila-Casado, C., Soto, V., Nepomuceno, T., Rodriguez-Iturbe, B., Johnson, R. J., & Herrera-Acosta, J. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00074.x · Cited by 556
Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort
Iseki, K., Ikemiya, Y., Inoue, T., Iseki, C., Kinjo, K., & Takishita, S. (2004) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(04)00934-5 · Cited by 526
Hyperuricemia in Primary and Renal Hypertension
Cannon, P. J., Stason, W. B., Demartini, F. E., Sommers, S. C., & Laragh, J. H. (1966) · New England Journal of Medicine · doi:10.1056/nejm196609012750902 · Cited by 505
Allopurinol Improves Endothelial Dysfunction in Chronic Heart Failure
Farquharson, C. A. J., Butler, R., Hill, A., Belch, J. J. F., & Struthers, A. D. (2002) · Circulation · doi:10.1161/01.cir.0000022140.61460.1d · Cited by 504
Rao, G. N., Corson, M. A., & Berk, B. C. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)93017-6 · Cited by 391
Xanthine Oxidase Is Involved in Free Radical Production in Type 1 Diabetes
Desco, M.-C., Asensi, M., Márquez, R., Martínez-Valls, J., Vento, M., Pallardó, F. V., Sastre, J., & Viña, J. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1118 · Cited by 390
ISEKI, K., OSHIRO, S., TOZAWA, M., ISEKI, C., IKEMIYA, Y., & TAKISHITA, S. (2001) · Hypertension Research · doi:10.1291/hypres.24.691 · Cited by 386
SELBY, J. V., FRIEDMAN, G. D., & QUESENBERRY, C. P. (1990) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115593 · Cited by 327
Physiological regulation of cyclooxygenase-2 in the kidney
Harris, R. C., & Breyer, M. D. (2001) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.2001.281.1.f1 · Cited by 301
Mild hyperuricemia induces glomerular hypertension in normal rats
Sánchez-Lozada, L. G., Tapia, E., Avila-Casado, C., Soto, V., Franco, M., Santamaría, J., Nakagawa, T., Rodríguez-Iturbe, B., Johnson, R. J., & Herrera-Acosta, J. (2002) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00170.2002 · Cited by 297
Essential Hypertension, Progressive Renal Disease, and Uric Acid: A Pathogenetic Link?
Johnson, R. J., Segal, M. S., Srinivas, T., Ejaz, A., Mu, W., Roncal, C., Sánchez-Lozada, L. G., Gersch, M., Rodriguez-Iturbe, B., Kang, D.-H., et al. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005010063 · Cited by 280
Hyperuricemia Causes Glomerular Hypertrophy in the Rat
Nakagawa, T., Mazzali, M., Kang, D.-H., Kanellis, J., Watanabe, S., Sanchez-Lozada, L. G., Rodriguez-Iturbe, B., Herrera-Acosta, J., & Johnson, R. J. (2003) · American Journal of Nephrology · doi:10.1159/000066303 · Cited by 269
Serum uric acid and hypertension: the Olivetti heart study.
Jossa, F., Farinaro, E., Panico, S., Krogh, V., Celentano, E., Galasso, R., Mancini, M., & Trevisan, M. (1994) · PubMed · Cited by 266
Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy
Syrjänen, J., Mustonen, J., & Pasternack, A. (2000) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/15.1.34 · Cited by 257
Serum Uric Acid and Renal Prognosis in Patients with IgA Nephropathy
Ohno, I., Hosoya, T., Gomi, H., Ichida, K., Okabe, H., & Hikita, M. (2001) · Nephron · doi:10.1159/000045939 · Cited by 169
Hypouricemia and hyperuricemia in type 2 diabetes: two different phenotypes
Bo, S., Cavallo‐Perin, P., Gentile, L., Repetti, E., & Pagano, G. (2001) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2001.00812.x · Cited by 162
Uric acid as a cardiovascular risk factor in arterial hypertension
Puig, J. G., & Ruilope, L. M. (1999) · Journal of Hypertension · doi:10.1097/00004872-199917070-00001 · Cited by 147
PRECURSORS OF ESSENTIAL HYPERTENSION
Selby, J. V., FRIEDMAN, G. D., & Quesenberry, C. P. (1989) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115123 · Cited by 105
Effect of chronic experimental renal insufficiency on urate metabolism.
Vaziri, N. D., Freel, R. W., & Hatch, M. (1995) · Journal of the American Society of Nephrology · doi:10.1681/asn.v641313 · Cited by 104
Role of oxygen radicals in tourniquet-related ischemia-reperfusion injury of human patients
Friedl, H. P., Till, G. O., Trentz, O., & Ward, P. A. (1991) · Journal of Molecular Medicine · doi:10.1007/bf01645168 · Cited by 53
Afshari, M., Larijani, B. A., Rezaie, A. R., Mojtahedi, A., Zamani, M. J., Astanehi-Asghari, F., Mostafalou, S., Hossein‐Nezhad, A., Heshmat, R., & Abdollahi, M. R. (2004) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2004.09.012 · Cited by 51
Cited by
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
Uric Acid and Cardiovascular Risk
Feig, D. I., Kang, D.-H., & Johnson, R. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0800885 · Cited by 2,440
Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients
Eckardt, K.-U., Kasiske, B. L., & Zeier, M. G. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02834.x · Cited by 1,499
Johnson, R. J., Segal, M. S., Sautin, Y., Nakagawa, T., Feig, D. I., Kang, D.-H., Gersch, M. S., Benner, S., & Sánchez-Lozada, L. G. (2007) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.4.899 · Cited by 1,075
Effect of Allopurinol in Chronic Kidney Disease Progression and Cardiovascular Risk
Goicoechea, M., de Vinuesa, S. G., Verdalles, U., Ruiz-Caro, C., Ampuero, J., Rincón, A., Arroyo, D., & Luño, J. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01580210 · Cited by 834
Metadata
- Authors
- Siu, Y.-P., Leung, K.-T., Tong, M. K.-H., & Kwan, T.-H.
- Venue
- American Journal of Kidney Diseases
- Publisher
- Elsevier BV
- Published
- 2006-01
- Volume
- 47
- Issue
- 1
- Pages
- 51-59
- ISSN
- 0272-6386 (ISSN-L)
- OpenAlex
- W2104681259
- Cited by
- 834
- References
- 27
- FWCI
- 11.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.